Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP)

D. Wolf; S. Mustjoki; B. -T Gjertsen; G. Gastl; M. Baldauf; Z. Trajanoski; F. Giles; A. Hochhaus; T. Ernst; T. Schenk; J. Janssen; K. Porkka; S. Sopper

Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP)

D. Wolf, S. Mustjoki, B. -T Gjertsen, G. Gastl, M. Baldauf, Z. Trajanoski, F. Giles, A. Hochhaus, T. Ernst, T. Schenk, J. Janssen, K. Porkka, S. Sopper

Intensive care medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	39-39
Journal	ONCOLOGY RESEARCH AND TREATMENT
Volume	39
Publication status	Published - Oct 2016

Cite this

Wolf, D., Mustjoki, S., Gjertsen, B. -T., Gastl, G., Baldauf, M., Trajanoski, Z., ... Sopper, S. (2016). Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP). ONCOLOGY RESEARCH AND TREATMENT, 39, 39-39.

Wolf, D. ; Mustjoki, S. ; Gjertsen, B. -T ; Gastl, G. ; Baldauf, M. ; Trajanoski, Z. ; Giles, F. ; Hochhaus, A. ; Ernst, T. ; Schenk, T. ; Janssen, J. ; Porkka, K. ; Sopper, S. / Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP). In: ONCOLOGY RESEARCH AND TREATMENT. 2016 ; Vol. 39. pp. 39-39.

@article{0881fd477bf04a9b83948539e7803caa,

title = "Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP)",

author = "D. Wolf and S. Mustjoki and Gjertsen, {B. -T} and G. Gastl and M. Baldauf and Z. Trajanoski and F. Giles and A. Hochhaus and T. Ernst and T. Schenk and J. Janssen and K. Porkka and S. Sopper",

year = "2016",

month = "10",

language = "English",

volume = "39",

pages = "39--39",

journal = "ONCOLOGY RESEARCH AND TREATMENT",

issn = "2296-5270",

publisher = "S. Karger AG",

}

Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP). / Wolf, D.; Mustjoki, S.; Gjertsen, B. -T; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Porkka, K.; Sopper, S.

In: ONCOLOGY RESEARCH AND TREATMENT, Vol. 39, 10.2016, p. 39-39.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP)

AU - Wolf, D.

AU - Mustjoki, S.

AU - Gjertsen, B. -T

AU - Gastl, G.

AU - Baldauf, M.

AU - Trajanoski, Z.

AU - Giles, F.

AU - Hochhaus, A.

AU - Ernst, T.

AU - Schenk, T.

AU - Janssen, J.

AU - Porkka, K.

AU - Sopper, S.

PY - 2016/10

Y1 - 2016/10

M3 - Article

VL - 39

SP - 39

EP - 39

JO - ONCOLOGY RESEARCH AND TREATMENT

JF - ONCOLOGY RESEARCH AND TREATMENT

SN - 2296-5270

ER -